Cingulate Inc. Files 8-K Report

TL;DR

Cingulate Inc. filed an 8-K, check for material updates.

AI Summary

On October 14, 2025, Cingulate Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures, other events, and financial statements and exhibits. No specific financial figures or material events beyond the filing itself were detailed in the provided text.

Why It Matters

This 8-K filing indicates that Cingulate Inc. is providing updates or disclosures to the SEC, which could contain material information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing notification and does not contain specific financial or operational details that would indicate high risk.

Key Players & Entities

• Cingulate Inc. (company) — Registrant
• October 14, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-40874 (identifier) — Commission File Number
• 86-3825535 (identifier) — IRS Employer Identification No.
• 1901 W. 47th Place, Kansas City, KS 66205 (address) — Principal executive offices
• (913) 942-2300 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share CING The Nasdaq Stock Mar

Filing Documents

• form8-k.htm (8-K) — 44KB
• ex99-1.htm (EX-99.1) — 27KB
• 0001493152-25-017931.txt ( ) — 283KB
• cing-20251014.xsd (EX-101.SCH) — 4KB
• cing-20251014_def.xml (EX-101.DEF) — 26KB
• cing-20251014_lab.xml (EX-101.LAB) — 36KB
• cing-20251014_pre.xml (EX-101.PRE) — 25KB
• form8-k_htm.xml (XML) — 6KB

From the Filing

UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 14, 2025 CINGULATE INC. (Exact name of registrant as specified in its charter) Delaware 001-40874 86-3825535 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 1901 W. 47th Place Kansas 66205 (Address of principal executive offices) (Zip Code) (913) 942-2300 (Registrant's telephone number, including area code) (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of exchange on which registered Common Stock, par value $0.0001 per share CING The Nasdaq Stock Market LLC (Nasdaq Capital Market) Warrants, exercisable for common stock CINGW The Nasdaq Stock Market LLC (Nasdaq Capital Market) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 7.01. Regulation FD Disclosure. On October 14, 2025, Cingulate Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has accepted for review the New Drug Application ("NDA") for CTx-1301 (dexmethylphenidate), the Company's lead candidate for the treatment of attention deficit/hyperactivity ("ADHD") for children and adults. The FDA has assigned a Prescription Drug User Fee Act ("PDUFA") target action date of May 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing. Item 8.01. Other Events. On October 14, 2025, the Company announced that the FDA has accepted for review the NDA for CTx-1301 (dexmethylphenidate), the Company's lead candidate for the treatment of ADHD for children and adults. The FDA has assigned a PDUFA target action date of May 31, 2026. Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated October 14, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CINGULATE INC. Dated: October 14, 2025 By: /s/ Jennifer L. Callahan Name: Jennifer L. Callahan Title: Interim Chief Executive Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR